Answers are grounded in this paper and cite their sources.
Activation of the CXCL12/CXCR4/ACKR3 axis is known to aid myocardial repair through ischemia-triggered hypoxia-inducible factor-1α (HIF-1α). To enhance the upregulation of HIF-1α, we administered roxadustat, a novel prolyl hydroxylase inhibitor (PHI) clinically approved by the European Medicines Agency 2021 for the treatment of renal anemia, with the purpose of improving LV function and attenuating ischemic cardiomyopathy.
No takes yet. Share an insight, caveat, or question.
Zaruba et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: